Last reviewed · How we verify
Basque Health Service — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
3 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| levo-bupicaine | levo-bupicaine | marketed | ||||
| Placebo evening | Placebo evening | marketed | ||||
| ASA evening | ASA evening | phase 3 | Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent | Cyclooxygenase-1 (COX-1), Cyclooxygenase-2 (COX-2) | Cardiovascular | |
| Acetylsalicylic morning | Acetylsalicylic morning | phase 3 | Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent | Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2) | Cardiovascular; Pain management; Inflammation | |
| Placebos morning | Placebos morning | phase 3 |
Therapeutic area mix
- Cardiovascular · 1
- Cardiovascular; Pain management; Inflammation · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Assistance Publique - Hôpitaux de Paris · 1 shared drug class
- Azienda Ospedaliera San Giovanni Battista · 1 shared drug class
- Biogen · 1 shared drug class
- Eli Lilly and Company · 1 shared drug class
- Harbin Medical University · 1 shared drug class
- Janssen Scientific Affairs, LLC · 1 shared drug class
- PLx Pharma · 1 shared drug class
- Royal College of Surgeons, Ireland · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Basque Health Service:
- Basque Health Service pipeline updates — RSS
- Basque Health Service pipeline updates — Atom
- Basque Health Service pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Basque Health Service — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/basque-health-service. Accessed 2026-05-16.